Catalent (NYSE:CTLT) Now Covered by StockNews.com

StockNews.com started coverage on shares of Catalent (NYSE:CTLT) in a research note issued on Saturday. The firm set a “sell” rating on the stock.

Other analysts also recently issued reports about the company. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $63.50 price target on shares of Catalent in a report on Thursday, July 11th. Barclays increased their price target on shares of Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research note on Friday, June 28th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Catalent has a consensus rating of “Hold” and a consensus target price of $56.83.

Catalent Stock Down 0.4 %

Shares of NYSE:CTLT opened at $59.55 on Friday. Catalent has a fifty-two week low of $31.80 and a fifty-two week high of $60.20. The firm’s 50 day moving average price is $57.63 and its 200 day moving average price is $56.71. The company has a quick ratio of 1.77, a current ratio of 2.51 and a debt-to-equity ratio of 1.37. The stock has a market cap of $10.78 billion, a price-to-earnings ratio of -9.76, a price-to-earnings-growth ratio of 2.47 and a beta of 1.16.

Insider Buying and Selling

In other news, insider Ricky Hopson sold 662 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $59.56, for a total transaction of $39,428.72. Following the completion of the sale, the insider now owns 29,974 shares in the company, valued at $1,785,251.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Catalent news, insider Ricky Hopson sold 662 shares of the business’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $59.56, for a total transaction of $39,428.72. Following the transaction, the insider now owns 29,974 shares in the company, valued at approximately $1,785,251.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Scott Gunther sold 666 shares of the stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $59.55, for a total value of $39,660.30. Following the transaction, the senior vice president now directly owns 39,635 shares of the company’s stock, valued at $2,360,264.25. The disclosure for this sale can be found here. Insiders have sold a total of 14,810 shares of company stock valued at $858,941 over the last quarter. 0.31% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Catalent

Large investors have recently made changes to their positions in the stock. Millennium Management LLC raised its position in shares of Catalent by 129.2% during the 2nd quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock worth $229,416,000 after purchasing an additional 2,299,784 shares during the last quarter. MBB Public Markets I LLC acquired a new position in shares of Catalent in the second quarter worth $788,000. APG Asset Management N.V. lifted its position in shares of Catalent by 26.8% in the second quarter. APG Asset Management N.V. now owns 155,466 shares of the company’s stock valued at $8,157,000 after acquiring an additional 32,900 shares in the last quarter. APG Asset Management US Inc. boosted its stake in shares of Catalent by 2.3% during the second quarter. APG Asset Management US Inc. now owns 52,861 shares of the company’s stock valued at $2,969,000 after acquiring an additional 1,172 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in Catalent by 7.6% during the 2nd quarter. AQR Capital Management LLC now owns 10,675 shares of the company’s stock worth $600,000 after purchasing an additional 750 shares in the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.